Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemiaRosa Lapalombella, John C. Byrd, Alicia Farmer et al.|Blood|2012Cited by 300
Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignanciesZachary A. Hing, Rosa Lapalombella, Ho Yee Joyce Fung et al.|Leukemia|2016Cited by 144
Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemiaJanek S. Walker, Rosa Lapalombella, Zachary A. Hing et al.|Journal of Hematology & Oncology|2021Cited by 55
Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic MalignanciesZachary A. Hing, Rosa Lapalombella, Ho Yee Joyce Fung et al.|Blood|2015Cited by 1
in chronic lymphocytic leukemia Selective inhibitors of nuclear export show that CRM1/XPO1 is a targetDilara McCauley, Yiming Zhong, Sharon Shacham et al.|Unknown|2013Cited by 0